Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial.

Cancer Immunol Immunother · 2021 · PMC8571235 · PMID 34351436

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Moreover, the circulating number of CD8 + CD28-CD127-CD39 + Treg, a CD8 + Treg subset that heavily infiltrates human cancer [ 44 , 45 ], showed a highly significant predicting value since reduced (with respect to baseline) levels of these cells at 180 days after GX301 vaccination predisposed patients to a prolonged survival.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.